Gunilla Enblad

Dec 29, 2023 | nature.com | Hui Wan |Xianhuo Wang |Dongbing Liu |Xiaofei Ye |Gunilla Enblad |Rose-Marie Amini | +3 more

AbstractDespite the improvements in clinical outcomes for DLBCL, a significant proportion of patients still face challenges with refractory/relapsed (R/R) disease after receiving first-line R-CHOP treatment. To further elucidate the underlying mechanism of R/R disease and to develop methods for identifying patients at risk of early disease progression, we integrated clinical, genetic and transcriptomic data derived from 2805 R-CHOP-treated patients from seven independent cohorts.